European journal of medicinal chemistryHumansProtein Kinase InhibitorsAnimalsProtein Serine-Threonine KinasesImmunotherapy
Discovery of highly selective and potent HPK1 inhibitors for cancer immunotherapy.
Wei Huang, Xiao-E Yan, Jingwen Wang, Yidan Zhang, Shan Li, Jia Hao, Baoding Zhang, Youning Ma, Xiangyu Li, Lin Zhu, Yunchuan Jia, Shuo Liu, Xin Huang, Cai-Hong Yun, Xianming Deng
Published: 202610.1016/j.ejmech.2025.118322
Abstract
Hematopoietic progenitor kinase 1 (HPK1) is an intracellular negative regulator of T cell receptor (TCR) signaling having been considered as an important target for cancer immunotherapy. Pharmacological studies in preclinical models have shown that t…
Preview only. Read the full abstract at the source